nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—CYP3A4—breast cancer	0.29	1	CbGaD
Avanafil—CYP3A4—Exemestane—breast cancer	0.058	0.133	CbGbCtD
Avanafil—CYP3A4—Letrozole—breast cancer	0.0493	0.113	CbGbCtD
Avanafil—CYP3A4—Anastrozole—breast cancer	0.044	0.101	CbGbCtD
Avanafil—CYP3A4—Toremifene—breast cancer	0.0402	0.0921	CbGbCtD
Avanafil—CYP3A4—Fulvestrant—breast cancer	0.0374	0.0856	CbGbCtD
Avanafil—CYP3A4—Thiotepa—breast cancer	0.0333	0.0763	CbGbCtD
Avanafil—CYP3A4—Ixabepilone—breast cancer	0.0305	0.0698	CbGbCtD
Avanafil—CYP3A4—Lapatinib—breast cancer	0.0293	0.0672	CbGbCtD
Avanafil—CYP3A4—Raloxifene—breast cancer	0.0222	0.0509	CbGbCtD
Avanafil—CYP3A4—Vinorelbine—breast cancer	0.0163	0.0373	CbGbCtD
Avanafil—CYP3A4—Tamoxifen—breast cancer	0.0147	0.0336	CbGbCtD
Avanafil—CYP3A4—Mitoxantrone—breast cancer	0.0143	0.0328	CbGbCtD
Avanafil—CYP3A4—Paclitaxel—breast cancer	0.0114	0.0262	CbGbCtD
Avanafil—CYP3A4—Irinotecan—breast cancer	0.0113	0.0258	CbGbCtD
Avanafil—CYP3A4—Vinblastine—breast cancer	0.01	0.023	CbGbCtD
Avanafil—CYP3A4—Docetaxel—breast cancer	0.00827	0.0189	CbGbCtD
Avanafil—CYP3A4—Doxorubicin—breast cancer	0.00616	0.0141	CbGbCtD
Avanafil—PDE5A—Platelet homeostasis—PDE2A—breast cancer	0.00156	0.0282	CbGpPWpGaD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—ITPR1—breast cancer	0.00154	0.0277	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—STIM1—breast cancer	0.00143	0.0258	CbGpPWpGaD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS2—breast cancer	0.0011	0.0198	CbGpPWpGaD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—SLCO1B1—breast cancer	0.00105	0.019	CbGpPWpGaD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS3—breast cancer	0.000884	0.0159	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—GUCY1A2—breast cancer	0.000685	0.0123	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—SLCO1B1—breast cancer	0.000674	0.0121	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—ITPR1—breast cancer	0.000598	0.0108	CbGpPWpGaD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—SLCO1B1—breast cancer	0.000577	0.0104	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—PLA2G4A—breast cancer	0.000559	0.0101	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—HRG—breast cancer	0.000558	0.0101	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—C1QBP—breast cancer	0.000519	0.00935	CbGpPWpGaD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—breast cancer	0.000497	0.00896	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—ABCC1—breast cancer	0.000493	0.00888	CbGpPWpGaD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—CYP2D6—breast cancer	0.000468	0.00842	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—ALDH3A2—breast cancer	0.000438	0.00788	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—NOS2—breast cancer	0.000428	0.00772	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—RAD51B—breast cancer	0.000423	0.00762	CbGpPWpGaD
Avanafil—CYP3A4—Liver X Receptor Pathway—FASN—breast cancer	0.000372	0.00671	CbGpPWpGaD
Avanafil—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—breast cancer	0.000369	0.00665	CbGpPWpGaD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—GSTM1—breast cancer	0.000361	0.0065	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SERPINB2—breast cancer	0.00036	0.00648	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—RAD51C—breast cancer	0.00036	0.00648	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—SULT1A1—breast cancer	0.000355	0.0064	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PDE2A—breast cancer	0.000351	0.00631	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—GSTA1—breast cancer	0.000347	0.00625	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—NOS3—breast cancer	0.000344	0.0062	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—ABCG2—breast cancer	0.000342	0.00616	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—KDM1A—breast cancer	0.000334	0.00602	CbGpPWpGaD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—ABCB1—breast cancer	0.000334	0.00601	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—STIM1—breast cancer	0.000321	0.00578	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—SULT1A1—breast cancer	0.000314	0.00566	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—BCHE—breast cancer	0.000283	0.0051	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—F3—breast cancer	0.00028	0.00505	CbGpPWpGaD
Avanafil—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—breast cancer	0.00028	0.00504	CbGpPWpGaD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—CYP2D6—breast cancer	0.000269	0.00484	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CFL1—breast cancer	0.000234	0.00421	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—GRB7—breast cancer	0.000232	0.00418	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—breast cancer	0.000227	0.00409	CbGpPWpGaD
Avanafil—CYP3A4—Xenobiotics—CYP2D6—breast cancer	0.000225	0.00405	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—breast cancer	0.000224	0.00404	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—NQO1—breast cancer	0.000221	0.00398	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VEGFC—breast cancer	0.000219	0.00394	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ALDOA—breast cancer	0.000219	0.00394	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP2D6—breast cancer	0.000216	0.00389	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—ALDH1A1—breast cancer	0.000214	0.00385	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—CYP1B1—breast cancer	0.000212	0.00382	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—breast cancer	0.000189	0.0034	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP1B1—breast cancer	0.000187	0.00337	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—COMT—breast cancer	0.000185	0.00334	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TGFB2—breast cancer	0.000184	0.00332	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—THBS1—breast cancer	0.000183	0.0033	CbGpPWpGaD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—breast cancer	0.000183	0.00329	CbGpPWpGaD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—breast cancer	0.000182	0.00328	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—GATA3—breast cancer	0.000181	0.00325	CbGpPWpGaD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—breast cancer	0.000176	0.00318	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—GSTM1—breast cancer	0.000169	0.00305	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IFNB1—breast cancer	0.000162	0.00292	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—CYP1A1—breast cancer	0.000161	0.00289	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—APC—breast cancer	0.000154	0.00277	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—breast cancer	0.000151	0.00273	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLAUR—breast cancer	0.000149	0.00268	CbGpPWpGaD
Avanafil—CYP3A4—Xenobiotics—CYP1A1—breast cancer	0.000148	0.00266	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLG—breast cancer	0.000146	0.00262	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP1A1—breast cancer	0.000142	0.00256	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—breast cancer	0.00014	0.00252	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PDGFA—breast cancer	0.000138	0.00249	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ITPR1—breast cancer	0.000134	0.00241	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ABL1—breast cancer	0.000133	0.0024	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—breast cancer	0.000131	0.00236	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—breast cancer	0.000128	0.0023	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLA2G4A—breast cancer	0.000125	0.00225	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—HGF—breast cancer	0.000125	0.00225	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CSF2—breast cancer	0.000124	0.00223	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—breast cancer	0.00011	0.00198	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CHST9—breast cancer	0.000107	0.00193	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—MMP1—breast cancer	0.000106	0.00192	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—breast cancer	0.000105	0.00189	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—breast cancer	0.000105	0.00189	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CDK2—breast cancer	0.000104	0.00188	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLAU—breast cancer	0.000104	0.00188	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CAV1—breast cancer	0.000102	0.00184	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CYP1B1—breast cancer	0.0001	0.0018	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—FN1—breast cancer	9.71e-05	0.00175	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—breast cancer	9.61e-05	0.00173	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS2—breast cancer	9.6e-05	0.00173	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—breast cancer	9.48e-05	0.00171	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CYP19A1—breast cancer	9.41e-05	0.00169	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—breast cancer	9.33e-05	0.00168	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3CG—breast cancer	9.3e-05	0.00167	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—breast cancer	9.21e-05	0.00166	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—EGF—breast cancer	9.19e-05	0.00165	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—breast cancer	9.16e-05	0.00165	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IGF1—breast cancer	8.51e-05	0.00153	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—AKT2—breast cancer	8.5e-05	0.00153	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3CD—breast cancer	8.17e-05	0.00147	CbGpPWpGaD
Avanafil—Dermatitis—Thiotepa—breast cancer	8.16e-05	0.000375	CcSEcCtD
Avanafil—Headache—Thiotepa—breast cancer	8.12e-05	0.000373	CcSEcCtD
Avanafil—Somnolence—Paclitaxel—breast cancer	8.12e-05	0.000373	CcSEcCtD
Avanafil—Palpitations—Capecitabine—breast cancer	8.11e-05	0.000373	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—breast cancer	8.09e-05	0.00146	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SERPINE1—breast cancer	8.08e-05	0.00146	CbGpPWpGaD
Avanafil—Chest pain—Docetaxel—breast cancer	8.07e-05	0.000371	CcSEcCtD
Avanafil—Arthralgia—Docetaxel—breast cancer	8.07e-05	0.000371	CcSEcCtD
Avanafil—Myalgia—Docetaxel—breast cancer	8.07e-05	0.000371	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ALB—breast cancer	8.07e-05	0.00145	CbGpPWpGaD
Avanafil—Nausea—Vinorelbine—breast cancer	8.06e-05	0.000371	CcSEcCtD
Avanafil—Dyspepsia—Paclitaxel—breast cancer	8.04e-05	0.000369	CcSEcCtD
Avanafil—Asthenia—Irinotecan—breast cancer	8.03e-05	0.000369	CcSEcCtD
Avanafil—Asthenia—Mitoxantrone—breast cancer	8.03e-05	0.000369	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	8.02e-05	0.000368	CcSEcCtD
Avanafil—Cough—Capecitabine—breast cancer	8.01e-05	0.000368	CcSEcCtD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—breast cancer	7.98e-05	0.00144	CbGpPWpGaD
Avanafil—Urinary tract infection—Epirubicin—breast cancer	7.95e-05	0.000366	CcSEcCtD
Avanafil—Hypertension—Capecitabine—breast cancer	7.93e-05	0.000364	CcSEcCtD
Avanafil—Dry mouth—Docetaxel—breast cancer	7.89e-05	0.000363	CcSEcCtD
Avanafil—Upper respiratory tract infection—Doxorubicin—breast cancer	7.89e-05	0.000363	CcSEcCtD
Avanafil—Gastrointestinal disorder—Paclitaxel—breast cancer	7.88e-05	0.000362	CcSEcCtD
Avanafil—Fatigue—Paclitaxel—breast cancer	7.87e-05	0.000362	CcSEcCtD
Avanafil—Pollakiuria—Doxorubicin—breast cancer	7.84e-05	0.000361	CcSEcCtD
Avanafil—Asthenia—Gemcitabine—breast cancer	7.82e-05	0.00036	CcSEcCtD
Avanafil—Arthralgia—Capecitabine—breast cancer	7.81e-05	0.000359	CcSEcCtD
Avanafil—Myalgia—Capecitabine—breast cancer	7.81e-05	0.000359	CcSEcCtD
Avanafil—Chest pain—Capecitabine—breast cancer	7.81e-05	0.000359	CcSEcCtD
Avanafil—Constipation—Paclitaxel—breast cancer	7.81e-05	0.000359	CcSEcCtD
Avanafil—Haematuria—Epirubicin—breast cancer	7.8e-05	0.000359	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—breast cancer	7.79e-05	0.0014	CbGpPWpGaD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	7.76e-05	0.000357	CcSEcCtD
Avanafil—Urinary tract disorder—Methotrexate—breast cancer	7.75e-05	0.000356	CcSEcCtD
Avanafil—Weight increased—Doxorubicin—breast cancer	7.73e-05	0.000355	CcSEcCtD
Avanafil—Epistaxis—Epirubicin—breast cancer	7.72e-05	0.000355	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—breast cancer	7.72e-05	0.00139	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS3—breast cancer	7.72e-05	0.00139	CbGpPWpGaD
Avanafil—Pruritus—Gemcitabine—breast cancer	7.71e-05	0.000355	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—breast cancer	7.71e-05	0.00139	CbGpPWpGaD
Avanafil—Nausea—Thiotepa—breast cancer	7.7e-05	0.000354	CcSEcCtD
Avanafil—Urethral disorder—Methotrexate—breast cancer	7.69e-05	0.000354	CcSEcCtD
Avanafil—Infection—Docetaxel—breast cancer	7.69e-05	0.000353	CcSEcCtD
Avanafil—Sinusitis—Epirubicin—breast cancer	7.68e-05	0.000353	CcSEcCtD
Avanafil—Diarrhoea—Mitoxantrone—breast cancer	7.66e-05	0.000352	CcSEcCtD
Avanafil—Diarrhoea—Irinotecan—breast cancer	7.66e-05	0.000352	CcSEcCtD
Avanafil—Dry mouth—Capecitabine—breast cancer	7.64e-05	0.000351	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—breast cancer	7.6e-05	0.00137	CbGpPWpGaD
Avanafil—Nervous system disorder—Docetaxel—breast cancer	7.59e-05	0.000349	CcSEcCtD
Avanafil—Pruritus—Fluorouracil—breast cancer	7.58e-05	0.000349	CcSEcCtD
Avanafil—CYP3A4—Tryptophan metabolism—CYP1A1—breast cancer	7.58e-05	0.00137	CbGpPWpGaD
Avanafil—Infestation—Doxorubicin—breast cancer	7.57e-05	0.000348	CcSEcCtD
Avanafil—Infestation NOS—Doxorubicin—breast cancer	7.57e-05	0.000348	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—breast cancer	7.56e-05	0.00136	CbGpPWpGaD
Avanafil—Tachycardia—Docetaxel—breast cancer	7.55e-05	0.000347	CcSEcCtD
Avanafil—Skin disorder—Docetaxel—breast cancer	7.52e-05	0.000345	CcSEcCtD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—breast cancer	7.51e-05	0.00135	CbGpPWpGaD
Avanafil—Diarrhoea—Gemcitabine—breast cancer	7.46e-05	0.000343	CcSEcCtD
Avanafil—Infection—Capecitabine—breast cancer	7.44e-05	0.000342	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—ALDH1A1—breast cancer	7.44e-05	0.00134	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—breast cancer	7.42e-05	0.00134	CbGpPWpGaD
Avanafil—Dizziness—Irinotecan—breast cancer	7.4e-05	0.00034	CcSEcCtD
Avanafil—Urinary tract infection—Doxorubicin—breast cancer	7.36e-05	0.000338	CcSEcCtD
Avanafil—Nervous system disorder—Capecitabine—breast cancer	7.35e-05	0.000338	CcSEcCtD
Avanafil—Eye disorder—Methotrexate—breast cancer	7.34e-05	0.000337	CcSEcCtD
Avanafil—Diarrhoea—Fluorouracil—breast cancer	7.34e-05	0.000337	CcSEcCtD
Avanafil—Tachycardia—Capecitabine—breast cancer	7.31e-05	0.000336	CcSEcCtD
Avanafil—PDE5A—Hemostasis—RAF1—breast cancer	7.3e-05	0.00131	CbGpPWpGaD
Avanafil—Cardiac disorder—Methotrexate—breast cancer	7.29e-05	0.000335	CcSEcCtD
Avanafil—Skin disorder—Capecitabine—breast cancer	7.28e-05	0.000334	CcSEcCtD
Avanafil—Urinary tract disorder—Epirubicin—breast cancer	7.25e-05	0.000333	CcSEcCtD
Avanafil—Oedema peripheral—Epirubicin—breast cancer	7.24e-05	0.000333	CcSEcCtD
Avanafil—Hypotension—Docetaxel—breast cancer	7.23e-05	0.000332	CcSEcCtD
Avanafil—Haematuria—Doxorubicin—breast cancer	7.22e-05	0.000332	CcSEcCtD
Avanafil—Connective tissue disorder—Epirubicin—breast cancer	7.22e-05	0.000332	CcSEcCtD
Avanafil—Body temperature increased—Paclitaxel—breast cancer	7.22e-05	0.000332	CcSEcCtD
Avanafil—Urethral disorder—Epirubicin—breast cancer	7.2e-05	0.000331	CcSEcCtD
Avanafil—Epistaxis—Doxorubicin—breast cancer	7.14e-05	0.000328	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PIK3CB—breast cancer	7.12e-05	0.00128	CbGpPWpGaD
Avanafil—Angiopathy—Methotrexate—breast cancer	7.12e-05	0.000327	CcSEcCtD
Avanafil—Vomiting—Irinotecan—breast cancer	7.12e-05	0.000327	CcSEcCtD
Avanafil—Vomiting—Mitoxantrone—breast cancer	7.12e-05	0.000327	CcSEcCtD
Avanafil—Sinusitis—Doxorubicin—breast cancer	7.1e-05	0.000326	CcSEcCtD
Avanafil—Immune system disorder—Methotrexate—breast cancer	7.09e-05	0.000326	CcSEcCtD
Avanafil—Dizziness—Fluorouracil—breast cancer	7.09e-05	0.000326	CcSEcCtD
Avanafil—Mediastinal disorder—Methotrexate—breast cancer	7.07e-05	0.000325	CcSEcCtD
Avanafil—Rash—Irinotecan—breast cancer	7.06e-05	0.000324	CcSEcCtD
Avanafil—Rash—Mitoxantrone—breast cancer	7.06e-05	0.000324	CcSEcCtD
Avanafil—Dermatitis—Mitoxantrone—breast cancer	7.05e-05	0.000324	CcSEcCtD
Avanafil—Dermatitis—Irinotecan—breast cancer	7.05e-05	0.000324	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Docetaxel—breast cancer	7.05e-05	0.000324	CcSEcCtD
Avanafil—Headache—Mitoxantrone—breast cancer	7.01e-05	0.000322	CcSEcCtD
Avanafil—Headache—Irinotecan—breast cancer	7.01e-05	0.000322	CcSEcCtD
Avanafil—Hypotension—Capecitabine—breast cancer	7e-05	0.000322	CcSEcCtD
Avanafil—Insomnia—Docetaxel—breast cancer	7e-05	0.000322	CcSEcCtD
Avanafil—Vomiting—Gemcitabine—breast cancer	6.93e-05	0.000319	CcSEcCtD
Avanafil—Somnolence—Docetaxel—breast cancer	6.88e-05	0.000316	CcSEcCtD
Avanafil—Mental disorder—Methotrexate—breast cancer	6.88e-05	0.000316	CcSEcCtD
Avanafil—Rash—Gemcitabine—breast cancer	6.87e-05	0.000316	CcSEcCtD
Avanafil—Dermatitis—Gemcitabine—breast cancer	6.87e-05	0.000316	CcSEcCtD
Avanafil—Eye disorder—Epirubicin—breast cancer	6.87e-05	0.000316	CcSEcCtD
Avanafil—Malnutrition—Methotrexate—breast cancer	6.83e-05	0.000314	CcSEcCtD
Avanafil—Headache—Gemcitabine—breast cancer	6.83e-05	0.000314	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Capecitabine—breast cancer	6.83e-05	0.000314	CcSEcCtD
Avanafil—Flushing—Epirubicin—breast cancer	6.82e-05	0.000313	CcSEcCtD
Avanafil—Cardiac disorder—Epirubicin—breast cancer	6.82e-05	0.000313	CcSEcCtD
Avanafil—Vomiting—Fluorouracil—breast cancer	6.82e-05	0.000313	CcSEcCtD
Avanafil—Dyspepsia—Docetaxel—breast cancer	6.81e-05	0.000313	CcSEcCtD
Avanafil—Insomnia—Capecitabine—breast cancer	6.78e-05	0.000311	CcSEcCtD
Avanafil—Rash—Fluorouracil—breast cancer	6.76e-05	0.000311	CcSEcCtD
Avanafil—Dermatitis—Fluorouracil—breast cancer	6.75e-05	0.00031	CcSEcCtD
Avanafil—Headache—Fluorouracil—breast cancer	6.72e-05	0.000309	CcSEcCtD
Avanafil—Urinary tract disorder—Doxorubicin—breast cancer	6.71e-05	0.000309	CcSEcCtD
Avanafil—Oedema peripheral—Doxorubicin—breast cancer	6.7e-05	0.000308	CcSEcCtD
Avanafil—Gastrointestinal disorder—Docetaxel—breast cancer	6.68e-05	0.000307	CcSEcCtD
Avanafil—Connective tissue disorder—Doxorubicin—breast cancer	6.68e-05	0.000307	CcSEcCtD
Avanafil—Fatigue—Docetaxel—breast cancer	6.67e-05	0.000307	CcSEcCtD
Avanafil—Angiopathy—Epirubicin—breast cancer	6.66e-05	0.000306	CcSEcCtD
Avanafil—Urethral disorder—Doxorubicin—breast cancer	6.66e-05	0.000306	CcSEcCtD
Avanafil—Nausea—Irinotecan—breast cancer	6.65e-05	0.000306	CcSEcCtD
Avanafil—Nausea—Mitoxantrone—breast cancer	6.65e-05	0.000306	CcSEcCtD
Avanafil—Immune system disorder—Epirubicin—breast cancer	6.64e-05	0.000305	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTA3—breast cancer	6.63e-05	0.00119	CbGpPWpGaD
Avanafil—Mediastinal disorder—Epirubicin—breast cancer	6.62e-05	0.000304	CcSEcCtD
Avanafil—Constipation—Docetaxel—breast cancer	6.62e-05	0.000304	CcSEcCtD
Avanafil—Back pain—Methotrexate—breast cancer	6.61e-05	0.000304	CcSEcCtD
Avanafil—Dyspepsia—Capecitabine—breast cancer	6.59e-05	0.000303	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—breast cancer	6.56e-05	0.00118	CbGpPWpGaD
Avanafil—Asthenia—Paclitaxel—breast cancer	6.55e-05	0.000301	CcSEcCtD
Avanafil—PDE5A—Hemostasis—IL2—breast cancer	6.54e-05	0.00118	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTA3—breast cancer	6.54e-05	0.00118	CbGpPWpGaD
Avanafil—Nausea—Gemcitabine—breast cancer	6.48e-05	0.000298	CcSEcCtD
Avanafil—Gastrointestinal disorder—Capecitabine—breast cancer	6.47e-05	0.000297	CcSEcCtD
Avanafil—Fatigue—Capecitabine—breast cancer	6.46e-05	0.000297	CcSEcCtD
Avanafil—Pruritus—Paclitaxel—breast cancer	6.46e-05	0.000297	CcSEcCtD
Avanafil—Vision blurred—Methotrexate—breast cancer	6.44e-05	0.000296	CcSEcCtD
Avanafil—Mental disorder—Epirubicin—breast cancer	6.44e-05	0.000296	CcSEcCtD
Avanafil—Constipation—Capecitabine—breast cancer	6.41e-05	0.000294	CcSEcCtD
Avanafil—Malnutrition—Epirubicin—breast cancer	6.39e-05	0.000294	CcSEcCtD
Avanafil—Nausea—Fluorouracil—breast cancer	6.37e-05	0.000293	CcSEcCtD
Avanafil—Eye disorder—Doxorubicin—breast cancer	6.35e-05	0.000292	CcSEcCtD
Avanafil—Cardiac disorder—Doxorubicin—breast cancer	6.31e-05	0.00029	CcSEcCtD
Avanafil—Flushing—Doxorubicin—breast cancer	6.31e-05	0.00029	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—breast cancer	6.26e-05	0.00113	CbGpPWpGaD
Avanafil—Diarrhoea—Paclitaxel—breast cancer	6.25e-05	0.000287	CcSEcCtD
Avanafil—Back pain—Epirubicin—breast cancer	6.19e-05	0.000284	CcSEcCtD
Avanafil—Angiopathy—Doxorubicin—breast cancer	6.17e-05	0.000283	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—breast cancer	6.17e-05	0.00111	CbGpPWpGaD
Avanafil—Muscle spasms—Epirubicin—breast cancer	6.15e-05	0.000283	CcSEcCtD
Avanafil—Immune system disorder—Doxorubicin—breast cancer	6.14e-05	0.000282	CcSEcCtD
Avanafil—Vertigo—Methotrexate—breast cancer	6.14e-05	0.000282	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—breast cancer	6.13e-05	0.0011	CbGpPWpGaD
Avanafil—Mediastinal disorder—Doxorubicin—breast cancer	6.13e-05	0.000282	CcSEcCtD
Avanafil—Body temperature increased—Docetaxel—breast cancer	6.12e-05	0.000281	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTA4—breast cancer	6.06e-05	0.00109	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—breast cancer	6.05e-05	0.00109	CbGpPWpGaD
Avanafil—Dizziness—Paclitaxel—breast cancer	6.04e-05	0.000277	CcSEcCtD
Avanafil—Vision blurred—Epirubicin—breast cancer	6.03e-05	0.000277	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—GSTA4—breast cancer	5.98e-05	0.00108	CbGpPWpGaD
Avanafil—Cough—Methotrexate—breast cancer	5.96e-05	0.000274	CcSEcCtD
Avanafil—Mental disorder—Doxorubicin—breast cancer	5.95e-05	0.000274	CcSEcCtD
Avanafil—Body temperature increased—Capecitabine—breast cancer	5.92e-05	0.000272	CcSEcCtD
Avanafil—Malnutrition—Doxorubicin—breast cancer	5.92e-05	0.000272	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTA2—breast cancer	5.91e-05	0.00106	CbGpPWpGaD
Avanafil—Agitation—Epirubicin—breast cancer	5.88e-05	0.00027	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—SULT1A1—breast cancer	5.84e-05	0.00105	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GPX2—breast cancer	5.83e-05	0.00105	CbGpPWpGaD
Avanafil—Arthralgia—Methotrexate—breast cancer	5.82e-05	0.000267	CcSEcCtD
Avanafil—Chest pain—Methotrexate—breast cancer	5.82e-05	0.000267	CcSEcCtD
Avanafil—Myalgia—Methotrexate—breast cancer	5.82e-05	0.000267	CcSEcCtD
Avanafil—Vomiting—Paclitaxel—breast cancer	5.8e-05	0.000267	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	5.78e-05	0.000266	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—GPX4—breast cancer	5.76e-05	0.00104	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—SULT1A1—breast cancer	5.76e-05	0.00104	CbGpPWpGaD
Avanafil—Rash—Paclitaxel—breast cancer	5.76e-05	0.000265	CcSEcCtD
Avanafil—Dermatitis—Paclitaxel—breast cancer	5.75e-05	0.000264	CcSEcCtD
Avanafil—Vertigo—Epirubicin—breast cancer	5.75e-05	0.000264	CcSEcCtD
Avanafil—Back pain—Doxorubicin—breast cancer	5.72e-05	0.000263	CcSEcCtD
Avanafil—Headache—Paclitaxel—breast cancer	5.72e-05	0.000263	CcSEcCtD
Avanafil—PDE5A—Hemostasis—SRC—breast cancer	5.71e-05	0.00103	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTA1—breast cancer	5.7e-05	0.00103	CbGpPWpGaD
Avanafil—Muscle spasms—Doxorubicin—breast cancer	5.69e-05	0.000261	CcSEcCtD
Avanafil—Palpitations—Epirubicin—breast cancer	5.65e-05	0.00026	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—NAT2—breast cancer	5.64e-05	0.00102	CbGpPWpGaD
Avanafil—Cough—Epirubicin—breast cancer	5.58e-05	0.000256	CcSEcCtD
Avanafil—Vision blurred—Doxorubicin—breast cancer	5.58e-05	0.000256	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—NAT2—breast cancer	5.56e-05	0.001	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VEGFA—breast cancer	5.56e-05	0.001	CbGpPWpGaD
Avanafil—Asthenia—Docetaxel—breast cancer	5.55e-05	0.000255	CcSEcCtD
Avanafil—Infection—Methotrexate—breast cancer	5.54e-05	0.000255	CcSEcCtD
Avanafil—Hypertension—Epirubicin—breast cancer	5.52e-05	0.000254	CcSEcCtD
Avanafil—Pruritus—Docetaxel—breast cancer	5.47e-05	0.000252	CcSEcCtD
Avanafil—Nervous system disorder—Methotrexate—breast cancer	5.47e-05	0.000251	CcSEcCtD
Avanafil—Arthralgia—Epirubicin—breast cancer	5.44e-05	0.00025	CcSEcCtD
Avanafil—Chest pain—Epirubicin—breast cancer	5.44e-05	0.00025	CcSEcCtD
Avanafil—Myalgia—Epirubicin—breast cancer	5.44e-05	0.00025	CcSEcCtD
Avanafil—Agitation—Doxorubicin—breast cancer	5.44e-05	0.00025	CcSEcCtD
Avanafil—Nausea—Paclitaxel—breast cancer	5.42e-05	0.000249	CcSEcCtD
Avanafil—Skin disorder—Methotrexate—breast cancer	5.42e-05	0.000249	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.41e-05	0.000248	CcSEcCtD
Avanafil—Asthenia—Capecitabine—breast cancer	5.37e-05	0.000247	CcSEcCtD
Avanafil—Dry mouth—Epirubicin—breast cancer	5.32e-05	0.000245	CcSEcCtD
Avanafil—Vertigo—Doxorubicin—breast cancer	5.32e-05	0.000244	CcSEcCtD
Avanafil—Pruritus—Capecitabine—breast cancer	5.3e-05	0.000244	CcSEcCtD
Avanafil—Diarrhoea—Docetaxel—breast cancer	5.29e-05	0.000243	CcSEcCtD
Avanafil—PDE5A—Hemostasis—MAPK3—breast cancer	5.26e-05	0.000947	CbGpPWpGaD
Avanafil—Palpitations—Doxorubicin—breast cancer	5.23e-05	0.00024	CcSEcCtD
Avanafil—Hypotension—Methotrexate—breast cancer	5.21e-05	0.00024	CcSEcCtD
Avanafil—Infection—Epirubicin—breast cancer	5.18e-05	0.000238	CcSEcCtD
Avanafil—Cough—Doxorubicin—breast cancer	5.16e-05	0.000237	CcSEcCtD
Avanafil—Diarrhoea—Capecitabine—breast cancer	5.13e-05	0.000236	CcSEcCtD
Avanafil—Nervous system disorder—Epirubicin—breast cancer	5.12e-05	0.000235	CcSEcCtD
Avanafil—Dizziness—Docetaxel—breast cancer	5.12e-05	0.000235	CcSEcCtD
Avanafil—Hypertension—Doxorubicin—breast cancer	5.11e-05	0.000235	CcSEcCtD
Avanafil—PDE5A—Hemostasis—TGFB1—breast cancer	5.1e-05	0.000919	CbGpPWpGaD
Avanafil—Tachycardia—Epirubicin—breast cancer	5.09e-05	0.000234	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Methotrexate—breast cancer	5.08e-05	0.000234	CcSEcCtD
Avanafil—Skin disorder—Epirubicin—breast cancer	5.07e-05	0.000233	CcSEcCtD
Avanafil—Insomnia—Methotrexate—breast cancer	5.04e-05	0.000232	CcSEcCtD
Avanafil—Arthralgia—Doxorubicin—breast cancer	5.04e-05	0.000232	CcSEcCtD
Avanafil—Chest pain—Doxorubicin—breast cancer	5.04e-05	0.000232	CcSEcCtD
Avanafil—Myalgia—Doxorubicin—breast cancer	5.04e-05	0.000232	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5e-05	0.00023	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—breast cancer	4.97e-05	0.000895	CbGpPWpGaD
Avanafil—Somnolence—Methotrexate—breast cancer	4.96e-05	0.000228	CcSEcCtD
Avanafil—Dizziness—Capecitabine—breast cancer	4.95e-05	0.000228	CcSEcCtD
Avanafil—Dry mouth—Doxorubicin—breast cancer	4.93e-05	0.000226	CcSEcCtD
Avanafil—Vomiting—Docetaxel—breast cancer	4.92e-05	0.000226	CcSEcCtD
Avanafil—Dyspepsia—Methotrexate—breast cancer	4.91e-05	0.000226	CcSEcCtD
Avanafil—Rash—Docetaxel—breast cancer	4.88e-05	0.000224	CcSEcCtD
Avanafil—Hypotension—Epirubicin—breast cancer	4.88e-05	0.000224	CcSEcCtD
Avanafil—Dermatitis—Docetaxel—breast cancer	4.87e-05	0.000224	CcSEcCtD
Avanafil—Headache—Docetaxel—breast cancer	4.85e-05	0.000223	CcSEcCtD
Avanafil—Gastrointestinal disorder—Methotrexate—breast cancer	4.81e-05	0.000221	CcSEcCtD
Avanafil—Fatigue—Methotrexate—breast cancer	4.81e-05	0.000221	CcSEcCtD
Avanafil—Infection—Doxorubicin—breast cancer	4.8e-05	0.00022	CcSEcCtD
Avanafil—Vomiting—Capecitabine—breast cancer	4.76e-05	0.000219	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Epirubicin—breast cancer	4.75e-05	0.000219	CcSEcCtD
Avanafil—Nervous system disorder—Doxorubicin—breast cancer	4.74e-05	0.000218	CcSEcCtD
Avanafil—PDE5A—Hemostasis—KRAS—breast cancer	4.73e-05	0.000851	CbGpPWpGaD
Avanafil—Rash—Capecitabine—breast cancer	4.72e-05	0.000217	CcSEcCtD
Avanafil—Insomnia—Epirubicin—breast cancer	4.72e-05	0.000217	CcSEcCtD
Avanafil—Dermatitis—Capecitabine—breast cancer	4.72e-05	0.000217	CcSEcCtD
Avanafil—Tachycardia—Doxorubicin—breast cancer	4.71e-05	0.000217	CcSEcCtD
Avanafil—Headache—Capecitabine—breast cancer	4.69e-05	0.000216	CcSEcCtD
Avanafil—Skin disorder—Doxorubicin—breast cancer	4.69e-05	0.000216	CcSEcCtD
Avanafil—CYP3A4—Tryptophan metabolism—MDM2—breast cancer	4.68e-05	0.000842	CbGpPWpGaD
Avanafil—Somnolence—Epirubicin—breast cancer	4.64e-05	0.000213	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—MTR—breast cancer	4.6e-05	0.000828	CbGpPWpGaD
Avanafil—Nausea—Docetaxel—breast cancer	4.6e-05	0.000211	CcSEcCtD
Avanafil—Dyspepsia—Epirubicin—breast cancer	4.59e-05	0.000211	CcSEcCtD
Avanafil—Hypotension—Doxorubicin—breast cancer	4.51e-05	0.000207	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—HPGDS—breast cancer	4.51e-05	0.000812	CbGpPWpGaD
Avanafil—Gastrointestinal disorder—Epirubicin—breast cancer	4.51e-05	0.000207	CcSEcCtD
Avanafil—Fatigue—Epirubicin—breast cancer	4.5e-05	0.000207	CcSEcCtD
Avanafil—Constipation—Epirubicin—breast cancer	4.46e-05	0.000205	CcSEcCtD
Avanafil—Nausea—Capecitabine—breast cancer	4.45e-05	0.000205	CcSEcCtD
Avanafil—Body temperature increased—Methotrexate—breast cancer	4.41e-05	0.000203	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.4e-05	0.000202	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTT1—breast cancer	4.37e-05	0.000787	CbGpPWpGaD
Avanafil—Insomnia—Doxorubicin—breast cancer	4.37e-05	0.000201	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PIK3CA—breast cancer	4.34e-05	0.000782	CbGpPWpGaD
Avanafil—Somnolence—Doxorubicin—breast cancer	4.29e-05	0.000197	CcSEcCtD
Avanafil—Dyspepsia—Doxorubicin—breast cancer	4.25e-05	0.000195	CcSEcCtD
Avanafil—PDE5A—Hemostasis—TP53—breast cancer	4.2e-05	0.000757	CbGpPWpGaD
Avanafil—Gastrointestinal disorder—Doxorubicin—breast cancer	4.17e-05	0.000192	CcSEcCtD
Avanafil—Fatigue—Doxorubicin—breast cancer	4.16e-05	0.000191	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—CYP17A1—breast cancer	4.14e-05	0.000745	CbGpPWpGaD
Avanafil—Constipation—Doxorubicin—breast cancer	4.13e-05	0.00019	CcSEcCtD
Avanafil—Body temperature increased—Epirubicin—breast cancer	4.13e-05	0.00019	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—PTGS1—breast cancer	4.1e-05	0.000738	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP17A1—breast cancer	4.08e-05	0.000735	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP2D6—breast cancer	4.02e-05	0.000724	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—HRAS—breast cancer	4.02e-05	0.000724	CbGpPWpGaD
Avanafil—Asthenia—Methotrexate—breast cancer	4e-05	0.000184	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—CYP2D6—breast cancer	3.96e-05	0.000714	CbGpPWpGaD
Avanafil—Pruritus—Methotrexate—breast cancer	3.95e-05	0.000181	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—NCOA2—breast cancer	3.94e-05	0.00071	CbGpPWpGaD
Avanafil—Body temperature increased—Doxorubicin—breast cancer	3.82e-05	0.000175	CcSEcCtD
Avanafil—Diarrhoea—Methotrexate—breast cancer	3.82e-05	0.000175	CcSEcCtD
Avanafil—Asthenia—Epirubicin—breast cancer	3.74e-05	0.000172	CcSEcCtD
Avanafil—Pruritus—Epirubicin—breast cancer	3.69e-05	0.00017	CcSEcCtD
Avanafil—Dizziness—Methotrexate—breast cancer	3.69e-05	0.000169	CcSEcCtD
Avanafil—Diarrhoea—Epirubicin—breast cancer	3.57e-05	0.000164	CcSEcCtD
Avanafil—PDE5A—Hemostasis—AKT1—breast cancer	3.55e-05	0.000639	CbGpPWpGaD
Avanafil—Vomiting—Methotrexate—breast cancer	3.55e-05	0.000163	CcSEcCtD
Avanafil—Rash—Methotrexate—breast cancer	3.52e-05	0.000162	CcSEcCtD
Avanafil—Dermatitis—Methotrexate—breast cancer	3.51e-05	0.000161	CcSEcCtD
Avanafil—Headache—Methotrexate—breast cancer	3.49e-05	0.000161	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—CYP1B1—breast cancer	3.48e-05	0.000627	CbGpPWpGaD
Avanafil—Asthenia—Doxorubicin—breast cancer	3.46e-05	0.000159	CcSEcCtD
Avanafil—Dizziness—Epirubicin—breast cancer	3.45e-05	0.000159	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—CYP1B1—breast cancer	3.44e-05	0.000619	CbGpPWpGaD
Avanafil—Pruritus—Doxorubicin—breast cancer	3.42e-05	0.000157	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—NCOA1—breast cancer	3.32e-05	0.000599	CbGpPWpGaD
Avanafil—Vomiting—Epirubicin—breast cancer	3.32e-05	0.000153	CcSEcCtD
Avanafil—Nausea—Methotrexate—breast cancer	3.31e-05	0.000152	CcSEcCtD
Avanafil—Diarrhoea—Doxorubicin—breast cancer	3.3e-05	0.000152	CcSEcCtD
Avanafil—Rash—Epirubicin—breast cancer	3.29e-05	0.000151	CcSEcCtD
Avanafil—Dermatitis—Epirubicin—breast cancer	3.29e-05	0.000151	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—CYP19A1—breast cancer	3.27e-05	0.00059	CbGpPWpGaD
Avanafil—Headache—Epirubicin—breast cancer	3.27e-05	0.00015	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—CYP19A1—breast cancer	3.23e-05	0.000582	CbGpPWpGaD
Avanafil—Dizziness—Doxorubicin—breast cancer	3.19e-05	0.000147	CcSEcCtD
Avanafil—Nausea—Epirubicin—breast cancer	3.1e-05	0.000142	CcSEcCtD
Avanafil—Vomiting—Doxorubicin—breast cancer	3.07e-05	0.000141	CcSEcCtD
Avanafil—Rash—Doxorubicin—breast cancer	3.04e-05	0.00014	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—COMT—breast cancer	3.04e-05	0.000548	CbGpPWpGaD
Avanafil—Dermatitis—Doxorubicin—breast cancer	3.04e-05	0.00014	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTP1—breast cancer	3.03e-05	0.000546	CbGpPWpGaD
Avanafil—Headache—Doxorubicin—breast cancer	3.03e-05	0.000139	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—COMT—breast cancer	3e-05	0.000541	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTP1—breast cancer	2.99e-05	0.000538	CbGpPWpGaD
Avanafil—Nausea—Doxorubicin—breast cancer	2.87e-05	0.000132	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTM1—breast cancer	2.78e-05	0.000502	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTM1—breast cancer	2.75e-05	0.000495	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP1A1—breast cancer	2.64e-05	0.000475	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP1A1—breast cancer	2.6e-05	0.000469	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SYNJ2—breast cancer	2.12e-05	0.000383	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NDUFS3—breast cancer	1.97e-05	0.000356	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CHST9—breast cancer	1.86e-05	0.000334	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—COX11—breast cancer	1.76e-05	0.000317	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CDA—breast cancer	1.61e-05	0.00029	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SHMT1—breast cancer	1.61e-05	0.00029	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC2A5—breast cancer	1.55e-05	0.000279	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLCO1B1—breast cancer	1.55e-05	0.000279	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APRT—breast cancer	1.5e-05	0.00027	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ESRRA—breast cancer	1.41e-05	0.000253	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ANGPTL4—breast cancer	1.41e-05	0.000253	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HADHB—breast cancer	1.33e-05	0.00024	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GPI—breast cancer	1.33e-05	0.00024	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALDH1A1—breast cancer	1.27e-05	0.000229	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALDH7A1—breast cancer	1.27e-05	0.000229	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—UMPS—breast cancer	1.22e-05	0.00022	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NME1—breast cancer	1.22e-05	0.00022	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—FHL2—breast cancer	1.22e-05	0.00022	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PHGDH—breast cancer	1.22e-05	0.00022	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ADSL—breast cancer	1.22e-05	0.00022	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—BRIP1—breast cancer	1.2e-05	0.000215	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LDHB—breast cancer	1.2e-05	0.000215	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HPSE—breast cancer	1.2e-05	0.000215	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCC1—breast cancer	1.13e-05	0.000204	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTA3—breast cancer	1.13e-05	0.000204	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMMR—breast cancer	1.13e-05	0.000204	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPARGC1B—breast cancer	1.1e-05	0.000198	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTA4—breast cancer	1.04e-05	0.000187	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CA9—breast cancer	1.04e-05	0.000187	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GPX2—breast cancer	1.01e-05	0.000182	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTA2—breast cancer	1.01e-05	0.000182	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SULT1A1—breast cancer	9.98e-06	0.00018	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GPX4—breast cancer	9.98e-06	0.00018	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTA1—breast cancer	9.75e-06	0.000176	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—IDH1—breast cancer	9.75e-06	0.000176	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NAT2—breast cancer	9.64e-06	0.000174	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MED12—breast cancer	8.45e-06	0.000152	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—DPYD—breast cancer	8.45e-06	0.000152	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALDOA—breast cancer	8.32e-06	0.00015	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOA3—breast cancer	8.08e-06	0.000146	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC2A2—breast cancer	8.02e-06	0.000145	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCG2—breast cancer	7.86e-06	0.000142	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTR—breast cancer	7.86e-06	0.000142	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CPT1A—breast cancer	7.86e-06	0.000142	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HPGDS—breast cancer	7.71e-06	0.000139	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HBA1—breast cancer	7.66e-06	0.000138	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ACHE—breast cancer	7.48e-06	0.000135	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTT1—breast cancer	7.48e-06	0.000135	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP17A1—breast cancer	7.08e-06	0.000127	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ENO1—breast cancer	7.01e-06	0.000126	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTGS1—breast cancer	7.01e-06	0.000126	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP2D6—breast cancer	6.87e-06	0.000124	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOA2—breast cancer	6.74e-06	0.000121	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—FASN—breast cancer	6.54e-06	0.000118	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—BCHE—breast cancer	6.51e-06	0.000117	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC5A5—breast cancer	6.43e-06	0.000116	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC2A1—breast cancer	6.21e-06	0.000112	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NQO1—breast cancer	6.21e-06	0.000112	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP1B1—breast cancer	5.96e-06	0.000107	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSP90AA1—breast cancer	5.84e-06	0.000105	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOA1—breast cancer	5.68e-06	0.000102	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—STK11—breast cancer	5.6e-06	0.000101	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP19A1—breast cancer	5.6e-06	0.000101	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—COMT—breast cancer	5.21e-06	9.38e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTP1—breast cancer	5.18e-06	9.33e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMOX1—breast cancer	5.11e-06	9.21e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ITPR1—breast cancer	5.1e-06	9.18e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCB1—breast cancer	4.91e-06	8.84e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TYMS—breast cancer	4.82e-06	8.68e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTM1—breast cancer	4.76e-06	8.58e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PLA2G4A—breast cancer	4.76e-06	8.58e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOR1—breast cancer	4.76e-06	8.58e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GPX1—breast cancer	4.56e-06	8.21e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP1A1—breast cancer	4.51e-06	8.13e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ERCC2—breast cancer	4.48e-06	8.06e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTHFR—breast cancer	4.21e-06	7.58e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CAV1—breast cancer	3.88e-06	6.99e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CG—breast cancer	3.54e-06	6.37e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CD—breast cancer	3.11e-06	5.6e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALB—breast cancer	3.07e-06	5.53e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NOS3—breast cancer	2.94e-06	5.29e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CB—breast cancer	2.71e-06	4.88e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTGS2—breast cancer	2.68e-06	4.84e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTEN—breast cancer	2.34e-06	4.22e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CA—breast cancer	1.65e-06	2.97e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AKT1—breast cancer	1.35e-06	2.43e-05	CbGpPWpGaD
